Biologics In Allergic Disease: Biologics For Asthma
Posted Date: Dec 7, 2019
- Investigator: Jonathan Bernstein
- Specialties:
- Type of Study: Observational/Survey
Novel biologic therapies (i.e., monoclonal antibodies) have been developed over the decades that have reformed the management of refractory allergic diseases. Conditions such as asthma and atopic dermatitis have a high prevalence but are a heterogeneous group of diseases despite similar clinical presentation and underlying pathophysiology. A better understanding of the phenotypes and endotypes of these diseases has driven rapid development of biologic medications targeting many steps of the inflammatory pathways. Although biologic medications are being preferred by healthcare providers in managing allergic/inflammatory respiratory and dermatologic disease, little is known about the provider preferences for attributes of biologic medications used in the treatment of severe asthma, atopic dermatitis, nasal polyposis, and chronic urticaria. To understand physician preferences for, and barriers to use of, biologic medications for the treatment of severe asthma, atopic dermatitis, nasal polyposis, and chronic urticaria, using a web-based (REDCap) physician questionnaire survey. AIMS 1. Determine the most frequently prescribed biologic for a specific disease, the duration of such prescriptions, and the patient parameter/s taken into consideration by the physicians while prescribing them. 2. Determine the criteria for choosing biologic over standard of care and the guidelines being followed for treating such condition 3. Determine the subjective perceptions of the physicians/allergist about the cost-effectiveness of biologics for specific conditions. METHODS On the REDCap platform, a cross-sectional study is designed involving a quantitative and qualitative open-ended, semi-structured questionnaire survey targeted to physicians and allergists who treat asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and chronic urticaria. Participating physicians will describe their practical preferences for attributes and barriers to use of biologic medications. They will rank and specify the significance of/preference for various levels of key attributes including mode of administration (subcutaneous vs. intravenous), perceived efficacy, efficacy in clinical trials, dosing frequency, cost-effectiveness, and time to onset of effect of the biologics for specific diseases.
Criteria:
Physicians Treating Asthma With Or Without Biologics In Clinical Practice
Keywords:
Biologics, Asthma, Allergy
For More Information:
Jonathan Bernstein
NULL
bernstja@ucmail.uc.edu